Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Bitcoin remains range-bound at $112K, experts say market looks for hints on further rate cuts
24/09/2025
Tata Investment shares surge 11%, hit fresh 52-week high. Here are 2 reasons for renewed buying
24/09/2025
Motilal Oswal initiates coverage on Sri Lotus Developers with Rs 250 target ; stock jumps over 5%
24/09/2025
Gold prices cool off by Rs 900 from highs after Fed remarks on potential rate cuts. Will the uptrend resume ?
24/09/2025
What makes Unimech, Solar Industries & Bharat Dynamics most expensive defence stocks - should you bet ?
24/09/2025
Trump says Gaza talks 'very successful with big players' despite disagreement over Palestine state recognition
24/09/2025
